Trial Profile

Effect of canagliflozin on cardiac function and baroreflex sensitivity in type 2 diabetic patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms J-CANDY study

Most Recent Events

26 Jun 2018 Results assessing the effect of Canagliflozin, on left ventricular diastolic dysfunction and baroreflex sensitivity at the same tim presented at the 78th Annual Scientific Sessions of the American Diabetes Association
06 Jan 2018 Status changed to completed.
11 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com